Detail (Long)
Offer self-administered DMPA subcutaneous injection as alternative, using shared decision-making.<sup>3</sup><br>
◦ May improve contraceptive access and ↑ reproductive autonomy<br>
◦ Recommendations same as for clinician-administered DMPA<br>
◦ No f/u needed<br>
◦ Self-administration is “off-label”<br>
◦ Higher rates of continuation vs. clinician-administered DMPA<br>
◦ Pregnancy rates low, similar to clinician-administered DMPA<br>
◦ May have higher rate of injection-site reactions, but no ↑ in other side effects/adverse events
◦ May improve contraceptive access and ↑ reproductive autonomy<br>
◦ Recommendations same as for clinician-administered DMPA<br>
◦ No f/u needed<br>
◦ Self-administration is “off-label”<br>
◦ Higher rates of continuation vs. clinician-administered DMPA<br>
◦ Pregnancy rates low, similar to clinician-administered DMPA<br>
◦ May have higher rate of injection-site reactions, but no ↑ in other side effects/adverse events